Effect of Dominant-Negative Epidermal Growth Factor Receptors on Cardiomyocyte Hypertrophy

REFERENCES

• The World Health Report 2003: Shaping the Future. World Health Organization, Geneva 2003; 1–193
   Google Scholar
• Solomon S D, Zelenkofske S, McMurray J J, Finn P V, Velazquez E, Ertl G, Harsanyi A, Rouleau J L, Maggioni A, Kober L, White H, Van de Werf F, Pieper K, Califf R M, Pfeffer M A. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 2005; 352: 2581–2588
   PubMed Web of Science ®Google Scholar
• Hannan R D, Jenkins A, Jenkins A K, Brandenburger Y. Cardiac hypertrophy: A matter of translation. Clin Exp Pharmacol Physiol 2003; 30: 517–527
   PubMed Web of Science ®Google Scholar
• Frey N, Olson E N. Cardiac hypertrophy: The good, the bad, and the ugly. Annu Rev Physiol 2003; 65: 45–79
   PubMed Web of Science ®Google Scholar
• Shah B H, Catt K J. A central role of EGF receptor transactivation in angiotensin II–induced cardiac hypertrophy. Trends Pharmacol Sci 2003; 24: 239–244
   PubMed Web of Science ®Google Scholar
• Thomas W G, Brandenburger Y, Autelitano D J, Pham T, Qian H, Hannan R D. Adenoviral-directed expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor. Circ Res 2002; 90: 135–142
   PubMed Web of Science ®Google Scholar
• Paradis P, Dali-Youcef N, Paradis F W, Thibault G, Nemer M. Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci USA 2000; 97: 931–936
   PubMed Web of Science ®Google Scholar
• Dostal D E, Baker K M. Angiotensin II stimulation of left ventricular hypertrophy in adult rat heart. Mediation by the AT1 receptor. Am J Hypertens 1992; 5: 276–280
   PubMed Web of Science ®Google Scholar
• Baker K M, Aceto J F. Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells. Am J Physiol 1990; 259: H610–618
   PubMed Web of Science ®Google Scholar
• Schunkert H, Jackson B, Tang S S, Schoen F J, Smits J F, Apstein C S, Lorell B H. Distribution and functional significance of cardiac angiotensin converting enzyme in hypertrophied rat hearts. Circulation 1993; 87: 1328–1339
   PubMed Web of Science ®Google Scholar
• Meggs L G, Coupet J, Huang H, Cheng W, Li P, Capasso J M, Homcy C J, Anversa P. Regulation of angiotensin II receptors on ventricular myocytes after myocardial infarction in rats. Circ Res 1993; 72: 1149–1162
   PubMed Web of Science ®Google Scholar
• Baker K M, Chernin M I, Wixson S K, Aceto J F. Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats. Am J Physiol 1990; 259: H324–332
   PubMed Web of Science ®Google Scholar
• De Rosa M L, Cardace P, Rossi M, Baiano A, de Cristofaro A. Comparative effects of chronic ACE inhibition and AT1 receptor blocked losartan on cardiac hypertrophy and renal function in hypertensive patients. J Hum Hypertens 2002; 16: 133–140
   PubMed Web of Science ®Google Scholar
• Thurmann P A. Angiotensin II antagonism and the heart: Valsartan in left ventricular hypertrophy. Cardiology 1999; 91: 3–7, Suppl 1
   PubMed Web of Science ®Google Scholar
• Kang P M, Landau A J, Eberhardt R T, Frishman W H. Angiotensin II receptor antagonists: A new approach to blockade of the renin-angiotensin system. Am Heart J 1994; 127: 1388–1401
   PubMed Web of Science ®Google Scholar
• De Gasparo M, Catt K J, Inagami T, Wright J W, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52: 415–472
   PubMed Web of Science ®Google Scholar
• Thomas W G. Regulation of angiotensin II type 1 (AT1) receptor function. Regul Pept 1999; 79: 9–23
   PubMed Web of Science ®Google Scholar
• Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, Ullrich A. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999; 402: 884–888
   PubMed Web of Science ®Google Scholar
• Daub H, Weiss F U, Wallasch C, Ullrich A. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 1996; 379: 557–560
   PubMed Web of Science ®Google Scholar
• Yahata Y, Shirakata Y, Tokumaru S, Yang L, Dai X, Tohyama M, Tsuda T, Sayama K, Iwai M, Horiuchi M, Hashimoto K. A novel function of angiotensin II in skin wound healing: Induction of fibroblast and keratinocyte migration by angiotensin II via heparin-binding epidermal growth factor (EGF)-like growth factor-mediated EGF receptor transactivation. J Biol Chem 2006; 281: 13209–13216
   PubMed Web of Science ®Google Scholar
• Gschwind A, Hart S, Fischer O M, Ullrich A. TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells. EMBO J 2003; 22: 2411–2421
   PubMed Web of Science ®Google Scholar
• Lin J, Freeman M R. Transactivation of ErbB1 and ErbB2 receptors by angiotensin II in normal human prostate stromal cells. Prostate 2003; 54: 1–7
   PubMed Web of Science ®Google Scholar
• Saito S, Frank G D, Motley E D, Dempsey P J, Utsunomiya H, Inagami T, Eguchi S. Metalloprotease inhibitor blocks angiotensin II-induced migration through inhibition of epidermal growth factor receptor transactivation. Biochem Biophys Res Commun 2002; 294: 1023–1029
   PubMed Web of Science ®Google Scholar
• Hao L, Du M, Lopez-Campistrous A, Fernandez-Patron C. Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstriction through the epidermal growth factor-receptor pathway. Circ Res 2004; 94: 68–76
   PubMed Web of Science ®Google Scholar
• Holbro T, Hynes N E. ErbB receptors: Directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol 2004; 44: 195–217
   PubMed Web of Science ®Google Scholar
• Burgess A W, Cho H S, Eigenbrot C, Ferguson K M, Garrett T P, Leahy D J, Lemmon M A, Sliwkowski M X, Ward C W, Yokoyama S. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 2003; 12: 541–552
   PubMed Web of Science ®Google Scholar
• Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103: 211–225
   PubMed Web of Science ®Google Scholar
• Olayioye M A, Neve R M, Lane H A, Hynes N E. The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J 2000; 19: 3159–3167
   PubMed Web of Science ®Google Scholar
• Hurwitz D R, Emanuel S L, Nathan M H, Sarver N, Ullrich A, Felder S, Lax I, Schlessinger J. EGF induces increased ligand binding affinity and dimerization of soluble epidermal growth factor (EGF) receptor extracellular domain. J Biol Chem 1991; 266: 22035–22043
   PubMed Web of Science ®Google Scholar
• Jones J T, Akita R W, Sliwkowski M X. Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett 1999; 447: 227–231
   PubMed Web of Science ®Google Scholar
• Shi W, Chen H, Sun J, Buckley S, Zhao J, Anderson K D, Williams R G, Warburton D. TACE is required for fetal murine cardiac development and modeling. Dev Biol 2003; 261: 371–380
   PubMed Web of Science ®Google Scholar
• Iwamoto R, Yamazaki S, Asakura M, Takashima S, Hasuwa H, Miyado K, Adachi S, Kitakaze M, Hashimoto K, Raab G, Nanba D, Higashiyama S, Hori M, Klagsbrun M, Mekada E. Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function. Proc Natl Acad Sci USA 2003; 100: 3221–3226
   PubMed Web of Science ®Google Scholar
• Ozcelik C, Erdmann B, Pilz B, Wettschureck N, Britsch S, Hubner N, Chien K R, Birchmeier C, Garratt A N. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci USA 2002; 99: 8880–8885
   PubMed Web of Science ®Google Scholar
• Erickson S L, O'Shea K S, Ghaboosi N, Loverro L, Frantz G, Bauer M, Lu L H, Moore M W. ErbB3 is required for normal cerebellar and cardiac development: A comparison with ErbB2-and heregulin-deficient mice. Development 1997; 124: 4999–5011
   PubMed Web of Science ®Google Scholar
• Meyer D, Birchmeier C. Multiple essential functions of neuregulin in development. Nature 1995; 378: 386–390
   PubMed Web of Science ®Google Scholar
• Slamon D J, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783–792
   PubMed Web of Science ®Google Scholar
• Rodrigues S, Attoub S, Nguyen Q D, Bruyneel E, Rodrigue C M, Westley B R, May F E, Thim L, Mareel M, Emami S, Gespach C. Selective abrogation of the proinvasive activity of the trefoil peptides pS2 and spasmolytic polypeptide by disruption of the EGF receptor signaling pathways in kidney and colonic cancer cells. Oncogene 2003; 22: 4488–4497
   PubMed Web of Science ®Google Scholar
• Redemann N, Holzmann B, von Ruden T, Wagner E F, Schlessinger J, Ullrich A. Anti-oncogenic activity of signalling-defective epidermal growth factor receptor mutants. Mol Cell Biol 1992; 12: 491–498
   PubMed Web of Science ®Google Scholar
• He T C, Zhou S, da Costa L T, Yu J, Kinzler K W, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95: 2509–2514
   PubMed Web of Science ®Google Scholar
• Iwaki K, Sukhatme V P, Shubeita H E, Chien K R. α-and β-adrenergic stimulation induces distinct patterns of immediate early gene expression in neonatal rat myocardial cells. fos/jun expression is associated with sarcomere assembly; Egr-1 induction is primarily an α1-mediated response. J Biol Chem 1990; 265: 13809–13817
   PubMed Web of Science ®Google Scholar
• Levitzki A, Gazit A. Tyrosine kinase inhibition: An approach to drug development. Science 1995; 267: 1782–1788
   PubMed Web of Science ®Google Scholar
• Osherov N, Levitzki A. Epidermal-growth-factor-dependent activation of the src-family kinases. Eur J Biochem 1994; 225: 1047–1053
   PubMedGoogle Scholar
• Matsui T, Li L, del Monte F, Fukui Y, Franke T F, Hajjar R J, Rosenzweig A. Adenoviral gene transfer of activated phosphatidylinositol 3′-kinase and Akt inhibits apoptosis of hypoxic cardiomyocytes in vitro. Circulation 1999; 100: 2373–2379
   PubMed Web of Science ®Google Scholar
• Andreev J, Galisteo M L, Kranenburg O, Logan S K, Chiu E S, Okigaki M, Cary L A, Moolenaar W H, Schlessinger J. Src and Pyk2 mediate G-protein-coupled receptor activation of epidermal growth factor receptor (EGFR) but are not required for coupling to the mitogen-activated protein (MAP) kinase signaling cascade. J Biol Chem 2001; 276: 20130–20135
   PubMedGoogle Scholar
• Drube S, Stirnweiss J, Valkova C, Liebmann C. Ligand-independent and EGF receptor-supported transactivation: Lessons from β2-adrenergic receptor signalling. Cell Signal 2006, (Epub ahead of print)
   Web of Science ®Google Scholar
• Lautrette A, Li S, Alili R, Sunnarborg S W, Burtin M, Lee D C, Friedlander G, Terzi F. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: A new therapeutic approach. Nat Med 2005; 11: 867–874
   PubMed Web of Science ®Google Scholar
• Buteau J, Foisy S, Joly E, Prentki M. Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes 2003; 52: 124–132
   PubMed Web of Science ®Google Scholar
• Janes P W, Saha N, Barton W A, Kolev M V, Wimmer-Kleikamp S H, Nievergall E, Blobel C P, Himanen J P, Lackmann M, Nikolov D B. Adam meets Eph: An ADAM substrate recognition module acts as a molecular switch for ephrin cleavage in trans. Cell 2005; 123: 291–304
   PubMed Web of Science ®Google Scholar
• Tikhomirov O, Carpenter G. Ligand-induced, p38-dependent apoptosis in cells expressing high levels of epidermal growth factor receptor and ErbB-2. J Biol Chem 2004; 279: 12988–12996
   PubMed Web of Science ®Google Scholar
• Giani C, Casalini P, Pupa S M, De Vecchi R, Ardini E, Colnaghi M I, Giordano A, Menard S. Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation. Oncogene 1998; 17: 425–432
   PubMedGoogle Scholar
• Crone S A, Zhao Y Y, Fan L, Gu Y, Minamisawa S, Liu Y, Peterson K L, Chen J, Kahn R, Condorelli G, Ross J, Jr, Chien K R, Lee K F. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002; 8: 459–465
   PubMed Web of Science ®Google Scholar
• Garrett T P, McKern N M, Lou M, Elleman T C, Adams T E, Lovrecz G O, Kofler M, Jorissen R N, Nice E C, Burgess A W, Ward C W. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell 2003; 11: 495–505
   PubMed Web of Science ®Google Scholar
• Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim J H, Saito K, Sakamoto A, Inoue M, Shirouzu M, Yokoyama S. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002; 110: 775–787
   PubMed Web of Science ®Google Scholar
• Garrett T P, McKern N M, Lou M, Elleman T C, Adams T E, Lovrecz G O, Zhu H J, Walker F, Frenkel M J, Hoyne P A, Jorissen R N, Nice E C, Burgess A W, Ward C W. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 2002; 110: 763–773
   PubMed Web of Science ®Google Scholar
• Sako Y, Ichinose J, Morimatsu M, Ohta K, Uyemura T. Optical bioimaging: from living tissue to a single molecule: Single-molecule visualization of cell signaling processes of epidermal growth factor receptor. J Pharmacol Sci 2003; 93: 253–258
   PubMed Web of Science ®Google Scholar
• Sako Y, Minoghchi S, Yanagida T. Single-molecule imaging of EGFR signalling on the surface of living cells. Nat Cell Biol 2000; 2: 168–172
   PubMed Web of Science ®Google Scholar
• Huang G C, Ouyang X, Epstein R J. Proxy activation of protein ErbB2 by heterologous ligands implies a heterotetrameric mode of receptor tyrosine kinase interaction. Biochem J 1998; 331: 113–119
   PubMed Web of Science ®Google Scholar
• Clayton A H, Walker F, Orchard S G, Henderson C, Fuchs D, Rothacker J, Nice E C, Burgess A W. Ligand-induced dimer-tetramer transition during the activation of the cell surface epidermal growth factor receptor-A multidimensional microscopy analysis. J Biol Chem 2005; 280: 30392–30399
   PubMed Web of Science ®Google Scholar
• Sharpe S, Barber K R, Grant C W. Interaction between ErbB-1 and ErbB-2 transmembrane domains in bilayer membranes. FEBS Lett 2002; 519: 103–107
   PubMed Web of Science ®Google Scholar
• Levkowitz G, Waterman H, Zamir E, Kam Z, Oved S, Langdon W Y, Beguinot L, Geiger B, Yarden Y. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev 1998; 12: 3663–3674
   PubMed Web of Science ®Google Scholar
• Lill N L, Douillard P, Awwad R A, Ota S, Lupher M L, Jr, Miyake S, Meissner-Lula N, Hsu V W, Band H. The evolutionarily conserved N-terminal region of Cbl is sufficient to enhance down-regulation of the epidermal growth factor receptor. J Biol Chem 2000; 275: 367–377
   PubMed Web of Science ®Google Scholar
• Thien C B, Walker F, Langdon W Y. RING finger mutations that abolish c-Cbl-directed polyubiquitination and downregulation of the EGF receptor are insufficient for cell transformation. Mol Cell 2001; 7: 355–365
   PubMed Web of Science ®Google Scholar
• Baulida J, Kraus M H, Alimandi M, Di Fiore P P, Carpenter G. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem 1996; 271: 5251–5257
   PubMed Web of Science ®Google Scholar